Editas Medicine (NASDAQ:EDIT) Stock, Quote.Headers.trade-ideas

Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Biotech

Earnings

Earnings Misses

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

AKRO

ANVS

EDIT

VRTX

Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.

Editas Q2 Earnings &amp; Revenues Miss Estimates, Stock Down

Dati deludenti sull'occupazione USA e i mercati crollano

Price Target

Pre-Market Outlook

BMBL

BOOT

CENTA

LYFT

PETQ

Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Intraday Update

Movers

ACMR

ADIL

ALHC

ANTE

APLT

BAND

BETS

BIDU

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

FLYW

GTLS

IFBD

IMNN

INGN

IXHL

KITT

LAZR

LFST

LMND

MSTR

MVLA

NRDY

NVAX

OCEA

OGEN

PAYO

PGNY

PSNY

QRTEA

RBOT

RVLV

RXRX

SMXT

TGTX

URBN

VANI

VIPS

VTNR

VTVT

VTYX

Shares of  Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Editas Medicine Inc

EDITA FOOD INDUSTRIES S.A.E GDR 144A

EDITA FOOD INDUSTRIES SAE GDR

EDITAS MEDICINE ORD

<p>RBC Capital  analyst Luca Issi   reiterates Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and maintains $8 price target.</p>


Reiteration

RBC Capital Reiterates Sector Perform on Editas Medicine, Maintains $8 Price Target

<p>Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Editas Medicine and provided 12-month price targets. The average target is $11.75, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 16.07% decline, the current average is now lower than the previous average price target of $14.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726606841_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Editas Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soumit Roy</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Editas Medicine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Editas Medicine's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Editas Medicine's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Editas Medicine analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Editas Medicine</h2>
<p>Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.</p>
<h3>Understanding the Numbers: Editas Medicine's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Editas Medicine's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-82.23%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Editas Medicine's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-13178.75%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-25.69%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-16.39%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Editas Medicine's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Editas Medicine Stands With Analysts

<p>Jones Trading  analyst Soumit Roy   initiates coverage on Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy rating and announces Price Target of $13.</p>


Initiation

Jones Trading Initiates Coverage On Editas Medicine with Buy Rating, Announces Price Target of $13

<p><strong>Editas Medicine, Inc</strong>. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.</p>
<p>Collaboration and other research and development (R&amp;D) revenues, which comprise the company&#39;s top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. The year-over-year decline in revenues can be attributed to reduced drug supply activity with collaborators.</p>
<p>Shares of Editas were down 12.2% on Aug 7 following the announcement of the results.</p>
<h3>Quarter in Detail</h3>
<p>In the second quarter of 2024, R&amp;D expenses increased 82% to $54.2 million compared with $29.8 million reported in the year-ago period. The massive uptick in R&amp;D expenses can be attributed to higher&nbsp;clinical and manufacturing costs related to the accelerated progression of Editas&#39; reni-cel program as well as costs attributable to&nbsp;other&nbsp;research activities.</p>
<p>General and administrative expenses were $18.2 million in the reported quarter, up 6% year over year, due to higher intellectual property and patent-related fees due to increased legal activity.</p>
<p>Editas had cash, cash equivalents and investments worth $318.3&nbsp;million as of Jun&nbsp;30, 2024, down from $376.8 million recorded as of Mar 31, 2024. The company expects its existing cash, cash equivalents and marketable securities, together with the near-term annual license fees and the contingent upfront payment from&nbsp;<strong>Vertex Pharmaceuticals&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>), to fund operating expenses and capital expenditure in 2026.</p>
<p>In late 2023, Vertex&nbsp;in-licensed&nbsp;rights to Editas&#39; Cas9 gene editing tool to develop its newly approved sickle cell disease gene therapy, Casgevy.</p>
<p>Shares of Editas have plunged 59.4% year to date compared with the&nbsp;industry&#39;s decline of 4.4%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/73699.jpg?v=2014758018" style="height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Pipeline Updates</h3>
<p>Editas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.</p>
<p>The company is evaluating the safety and efficacy of its investigational gene-editing medicine, reni-cel (renizgamglogene autogedtemcel, previously EDIT-301), in phase I/II/III RUBY study for treating SCD.</p>
<p>EDIT has completed enrollment and continues to dose SCD patients in the adult cohort of the RUBY study. The company has completed enrollment in the adolescent cohort of the RUBY study. Editas remains on track to report substantive data from the RUBY study by the end of 2024.</p>
<p>The company is also evaluating reni-cel for the treatment of transfusion-dependent beta thalassemia (TDT). Editas has completed enrollment in the adult cohort and continues to dose patients in the EdiTHAL study for TDT. The company is also on track to report additional clinical data from the EdiTHAL study by the end of 2024.</p>
<p>Please note that during the reported quarter, Editas reported&nbsp;new positive data from the RUBY study of reni-cel in 18 patients with SCD and the EdiTHAL study of the same in seven patients with TDT. In the expected data readout from the RUBY and EdiTHAL studies by year-end, EDIT will provide additional efficacy data.</p>
<div class="chart_embed">
<h3>Editas Medicine, Inc. Price and Consensus</h3>
<p><img alt="Editas Medicine, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/d5/1723118191.png" style="height:310px; width:600px" title="" /></p>
<p><span style="font-size:13px">Editas Medicine, Inc. price-consensus-chart</span><span style="font-size:13px"> | </span><span style="font-size:13px">Editas Medicine, Inc. Quote</span></p>
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
<p>Editas currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the biotech sector are <strong>Annovis Bio</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anvs#NYSE">ANVS</a>) and&nbsp;<strong>Akero Therapeutics </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>), each carrying a Zacks Rank #2 (Buy) at present.</p>
<p>In the past 60 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $1.95 to $1.91. Year to date, shares of ANVS have plunged 57.1%.</p>
<p>ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.</p>
<p>In the past 60 days, estimates for Akero Therapeutics&#39; 2024 loss per share have narrowed from $3.87 to $3.82. During the same period, loss per share estimates for 2025 have remained constant at $4.29. Year to date, shares of AKRO have gained 1.4%.</p>
<p>Akero&#39;s earnings beat estimates in one of the trailing four quarters, missed twice and matched once, delivering an average negative surprise of 5.10%.</p>
<p><a href="https://www.zacks.com/stock/news/2319312/editas-edit-q2-earnings-revenues-miss-estimates-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2319312">To read this article on Zacks.com click here.</a></p>


Editas Q2 Earnings & Revenues Miss Estimates, Stock Down

<p>Barclays  analyst Gena Wang   maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Equal-Weight and lowers the price target from $9 to $7.</p>


Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7

WIIM

Editas Medicine shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $13 to $15.

<p>Truist Securities  analyst Joon Lee   maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $20 to $12.</p>


Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $12

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="https://www.benzinga.com/analyst-stock-ratings"> analyst ratings page.</a></p>
<ul>
<li>Canaccord Genuity cut the price target for <strong>Lyft, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from $23 to $18. Canaccord Genuity analyst Michael Graham maintained a Buy rating. Lyft shares fell 17.2% to close at $9.08 on Wednesday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush slashed the price target for <strong>Dine Brands Global, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) from $37 to $34. Wedbush analyst Nick Setyan maintained the stock with a Neutral rating. Dine Brands Global shares fell 4.6% to close at $30.44 on Wednesday. <a href="https://www.benzinga.com/quote/DIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised <strong>Boot Barn Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) price target from $144 to $147. Piper Sandler analyst Peter Keith maintained an Overweight rating. Boot Barn shares fell 1.6% to close at $115.70 on Wednesday. <a href="https://www.benzinga.com/quote/BOOT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for <strong>Central Garden &amp; Pet Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from $38 to $34. JP Morgan analyst Andrea Faria Teixeira maintained a Neutral rating. Central Garden shares fell 1.1% to close at $32.70 on Wednesday. <a href="https://www.benzinga.com/quote/CENTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut <strong>Bumble Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) price target from $12 to $6. Morgan Stanley analyst Nathan Feather maintained an Equal-Weight rating. Bumble shares rose 1.9% to close at $8.06 on Wednesday. <a href="https://www.benzinga.com/quote/BMBL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted <strong>Editas Medicine, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) price target from $13 to $15. B of A Securities analyst Greg Harrison upgraded the stock from Neutral to Buy. Editas Medicine shares fell 12.2% to close at $4.11 on Wednesday. <a href="https://www.benzinga.com/quote/EDIT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for <strong>PetIQ, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETQ#NASDAQ">PETQ</a>) from $30 to $31. Truist Securities analyst Bill Chappell downgraded the stock from Buy to Hold. PetIQ shares gained 47.9% to close at $30.42 on Wednesday. <a href="https://www.benzinga.com/quote/PETQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut <strong>The Walt Disney Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $145 to $110. Needham analyst Laura Martin maintained a Buy rating. Disney shares fell 4.5% to close at $85.96 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird slashed <strong>Charles River Laboratories International, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) price target from $239 to $191. Baird analyst Eric Coldwell downgraded the stock from Outperform to Neutral. Charles River Laboratories shares fell 12.6% to close at $199.96 on Wednesday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut <strong>McKesson Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $694 to $671. Baird analyst Eric Coldwell maintained an Outperform rating. McKesson shares gained 0.5% to close at $617.51 on Wednesday. <a href="https://www.benzinga.com/analyst-stock-ratings">See how other analysts view this stock.</a></li>
</ul>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/08/40243140/us-stocks-decline-as-smcis-margin-miss-brings-nvidia-and-other-ai-stocks-under-pressure-investor-se">US Stocks Decline As SMCI&#8217;s Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In &#8216;Extreme Fear&#8217; Zone</a></strong></li>
</ul>


<p>B of A Securities  analyst Greg Harrison   upgrades Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Neutral to Buy and raises the price target from $13 to $15.</p>


Upgrades

B of A Securities Upgrades Editas Medicine to Buy, Raises Price Target to $15

Editas Medicine shares are trading lower after the company reported worse-than-expected Q2 financial results.

Guidance

Health Care

Editas Medicine' Cash Balance Of $318.3M Is Expected To Provide Cash Runway Into 2026

Editas Medicine Q2 2024 GAAP EPS $(0.82) Misses $(0.70) Estimate, Sales $513.000K Miss $5.083M Estimate

<p>Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1718730045_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Editas Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Perform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Liisa Bayko</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$7.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Samantha Semenkow</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Editas Medicine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Editas Medicine's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Editas Medicine's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Editas Medicine analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Editas Medicine</h2>
<p>Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.</p>
<h3>Breaking Down Editas Medicine's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Editas Medicine's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-88.48%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Editas Medicine's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5458.15%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Editas Medicine's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-19.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Editas Medicine's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-13.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Editas Medicine's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 5 Analyst Insights On Editas Medicine

<p>Oppenheimer  analyst Jay Olson   maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Perform and maintains $12 price target.</p>


Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target

<ul>
<li>All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel)&nbsp;infusion</li>
<li>Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant</li>
</ul>


Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA

<ul>
<li>All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel)&nbsp;infusion</li>
<li>Patients had early normalization of total hemoglobin with a mean within the normal range at &gt;14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of &gt;40%.</li>
<li>Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant</li>
</ul>


Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA

<p>Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1717084810_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Editas Medicine among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liisa Bayko</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$7.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Samantha Semenkow</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Editas Medicine. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Editas Medicine's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Editas Medicine analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Editas Medicine: A Closer Look</h2>
<p>Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.</p>
<h3>Financial Insights: Editas Medicine</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Editas Medicine's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately <strong>-88.48%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Editas Medicine's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-5458.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Editas Medicine's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-19.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Editas Medicine's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-13.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Editas Medicine's debt-to-equity ratio is below the industry average at <strong>0.12</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts

<p>Evercore ISI Group  analyst Liisa Bayko   maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a In-Line and lowers the price target from $15 to $7.</p>


Evercore ISI Group Maintains In-Line on Editas Medicine, Lowers Price Target to $7

<p>Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.<br /><br />&nbsp;</p>
<p>Clinical data from patients treated in the Phase 1/2/3 RUBY trial of reni-cel in patients with severe sickle cell disease and in the Phase 1/2 EdiTHAL trial of reni-cel in patients with transfusion-dependent beta thalassemia will be shared, including:</p>
<ul>
<li>RUBY trial, Abstract #S285, oral presentation on Saturday, June 15:
<ul>
<li>Clinical data on at least 18 patients, with 2-21 months follow-up.</li>
<li>Efficacy data, including total hemoglobin, fetal hemoglobin, and vaso-occlusive events (VOEs).</li>
<li>Safety data, including neutrophil and platelet engraftment.</li>
</ul>
</li>
<li>EdiTHAL trial, Abstract #P1476, poster presentation on Friday, June 14:
<ul>
<li>Clinical data on seven patients, with 4-12 months follow-up.</li>
<li>Efficacy data, including total hemoglobin, fetal hemoglobin, and transfusion independence.
<ul>
<li>Safety data, including neutrophil and platelet engraftment.</li>
</ul>
</li>
</ul>
</li>
</ul>


Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June

<p>The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Baltimore and virtually.</p>


Editas Medicine Reports Presentation Of Preclinical Data Demonstrating Several In Vivo Capabilities Towards Developing Transformative In Vivo Gene Editing Medicines

TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company's shares opened today at $4.88....

TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT)

Citi analyst Samantha Semenkow maintained a Buy rating on Editas Medicine (EDIT – Research Report) yesterday and set a price target of $15.00. Sama...

Buy Rating Reaffirmed for Editas Medicine Amidst Promising Clinical Advancements and Future Prospects

Bank of America Securities analyst Greg Harrison upgraded the rating on Editas Medicine (EDIT – Research Report) to a Buy yesterday, setting a pric...

Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments

BofA upgrades Editas to buy, cites reni-cel progress

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 7. Analyst Jack Allen fro...

Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Editas Medicine (EDIT) has received a new Buy rating, initiated by JonesTrading analyst, Soumit Roy. Soumit Roy has given his Buy rating due to a c...

Buy Rating Initiated for Editas Medicine Citing Superior Editing Platform and Market Potential

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a price target of...

Editas Medicine (EDIT) Receives a Hold from RBC Capital

BLUE

CRSP

Press Releases

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Editas Medicine

Editas Medicine (EDIT) Forecast

Editas Medicine (NASDAQ:EDIT) Stock, Quote.Headers.trade-ideas